Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
Aditxt, Inc. (NASDAQ: ADTX) (Aditxt or the Company), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Adimune, Inc. (Adimune...